British Society for Gene and Cell Therapy Annual meeting
Friday April 15th 2016
Institute of Child Health, 30 Guilford St, London WC1N 1EH

AAV in 2016: Biology, vector design and implementation into human gene therapy
Programme

	Friday 15th April			
	Time	**Speaker**	**Institution**	**Title**
	Session 1. Cutting edge vector technology and immunological challenges **Chairs: Stuart Nicklin and Ahad Rahim**			
	09:00 Registration and welcome tea & coffee			
	09:30 BSGCT Annual General Meeting			
INV01	10.00	Federico Mingozzi	Genethon, Evry	Overcoming humoral immune responses to AAV vectors
INV02	10.30	Hildegard Büning	University of Cologne	AAV-Host Interaction – Spotlight on liver
INV03	11.00	Ivana Trapani	TIGEM (Telethon Institute of Genetics and Medicine)	Dual AAV vectors for efficient and safe retinal gene transfer
FB01	11.30	*Fairbairn Presentation* Estrella Lopez	University of Glasgow	Dissecting immune responses to HAdV-5 in wild type and immunocompromised mouse serum reveals a new mechanism of transduction via the coxsackie and adenovirus receptor
FB02	11.45	*Fairbairn Presentation* Carmen Aguirre Hernandez	Queen Mary University of London	The adenoviral AdΔΔ mutant enhances mitoxantrone-induced cell death by promoting apoptosis and attenuating autophagy in prostate cancer cells.
	12.00-13.15 Lunch and posters (all even numbers 12:15-12:45, all odd numbers 12:45-13:15)			
LD01	**12.30-13.10 Lunchtime discussion session – Cell Therapy Catapult** Regulatory and Clinical Challenges in the translation of Gene Therapies, Natalie Mount Facilitator: Sian Harding			
	Session 2. Recent advances in pre-clinical knowledge **Chairs: Robin Ali and Claire Booth** *Kindly sponsored by Dimension Therapeutics*			
INV04	13.15	Matteo Rizzi	University College London	AAV-based optogenetic tools for retinal disease
INV05	13.45	Annalisa Jenkins	Dimension Therapeutics	Developing an AAV Pipeline and Building a Successful Biotech
INV06	14.15	Mark Kay	Stanford University	A xenograft liver model for selection of AAV variants
FB03	14.45	*Fairbairn Presentation* Julien Baruteau	University College London	AAV8-mediated gene therapy rescue of lethal Argininosuccinate lyase-deficient mice.
FB04	15.00	*Fairbairn Presentation* Joanne Ng	University College London	Novel therapeutic approaches for childhood parkinsonism
	15.15-15.35 Tea break and posters *Kindly sponsored by Athena Vision*			

British Society for Gene and Cell Therapy Annual meeting
Friday April 15th 2016
Institute of Child Health, 30 Guilford St, London WC1N 1EH

AAV in 2016: Biology, vector design and implementation into human gene therapy
Programme

	Kindly sponsored by Syncona **Session 3. Clinical experiences and future vision for AAV therapies** **Chairs: Andy Baker and Rajvinder Karda**			
INV07	15.35	Ian Alexander	CMRI Australia	Liver-Targeted Gene Therapy using rAAV
INV08	16.00	Patrick Most	uniQure & University of Heidelberg	S100A1 and its therapeutic use for heart failure
INV09	16:25	Roger Hajjar	Mt Sinai Hospital NY	Gene Therapy for Heart Failure: The Road Ahead
INV10	16:45	Robert Maclaren	University of Oxford	Clinical gene therapy for choroideremia
	17.05	A short comfort break		
KN01	*Kindly sponsored by Athena Vision* 17.15-18.00 **Keynote speaker**: David Schaffer, UC Berkeley, Engineering the AAV Capsid			
	Chair: Uta Griesenbach			
	18.00 Presentation of awards and close of conference			
	18.15 Networking drinks, The Marquis Cornwallis			